Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fibrin tissue adhesives

U Martinowitz1, W D Spotnitz

  • 1National Hemophilia Center, Chaim Sheba Medical Center, Tel Hashomer, Israel. Hemophila@trendline.co.il

Thrombosis and Haemostasis
|July 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current strategy for genetic analysis of haemophilia A families.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

The fixed flexed and subluxed knee in the haemophilic child: what should be done?

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Pharmacokinetic properties of two factor VIII concentrates with single and double viral inactivation.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

The feasibility of using concentrates containing factor IX for continuous infusion.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Continuous infusion instead of bolus injections of factor concentrate?

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Home therapy with continuous infusion of factor VIII after minor surgery or serious haemorrhage.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same journal

Discontinuation of Oral Anticoagulation After Successful Catheter Ablation for Atrial Fibrillation: Meta-analysis of Randomized Clinical Trials.

Thrombosis and haemostasis·2026
Same journal

Novel/Recurrent Variants in Pakistani Glanzmann Thrombasthenia and Glanzmann-like bleeding diathesis: Insights from NGS Analysis.

Thrombosis and haemostasis·2026
Same journal

Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders.

Thrombosis and haemostasis·2026
Same journal

The Interaction of Fibrin with Endothelial Cell Receptor N-Cadherin Promotes Fibrin-Dependent Angiogenesis.

Thrombosis and haemostasis·2026
Same journal

Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL AF Study Design.

Thrombosis and haemostasis·2026
Same journal

Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?

Thrombosis and haemostasis·2026
See all related articles

Tranexamic acid (FTA) shows potential in surgery for bleeding disorders and high-risk procedures. However, inconsistent data necessitates careful consideration of its formulation, application, and clear clinical benefit to ensure safe and effective use.

Area of Science:

  • Surgical hemostasis
  • Pharmacology of hemostatic agents
  • Blood product safety

Background:

  • Tranexamic acid (FTA) is recognized as a valuable adjunct in various surgical fields.
  • Its primary applications include managing bleeding disorders and minimizing postoperative hemorrhage in high-risk procedures.
  • Existing literature presents numerous case reports but lacks conclusive, well-controlled studies.

Purpose of the Study:

  • To critically evaluate the current evidence and controversies surrounding the use of FTA in surgery.
  • To highlight factors influencing FTA efficacy, including formulation, indication selection, and application techniques.
  • To emphasize the importance of understanding these variables for successful clinical implementation.

Main Methods:

  • Review and synthesis of existing reports and data on FTA usage across different surgical indications.

Related Experiment Videos

  • Analysis of factors contributing to variability and conflicting results in published studies.
  • Assessment of the impact of formulation, application methodology, and surgical expertise on outcomes.

    • Main Results:

    • Significant variability in FTA formulation, indication selection, application devices, and surgical skill contributes to contradictory findings.
    • A lack of well-controlled, conclusive studies hinders definitive assessment of FTA's efficacy for many indications.
    • The interpretation of results is complicated by the heterogeneity of reported data.

    Conclusions:

    • Understanding the nuances of FTA application and indication-specific requirements is crucial for optimizing its use.
    • As a blood product, FTA necessitates clear indications, even with viral inactivation techniques.
    • Contraindications for FTA exist when no clinically significant benefit is demonstrated for a specific use.